Duggan's continued investment in Pulse Biosciences (NASDAQ:PLSE) underscores his confidence in the company's prospects. Pulse Biosciences is involved in the development of medical devices and technologies, operating within the surgical and medical instruments sector. Based on InvestingPro's Fair Value analysis, the stock appears to be trading above its intrinsic value, despite showing strong momentum with a 47% gain over the past six months. Based on InvestingPro's Fair Value analysis, the stock appears to be trading above its intrinsic value, despite showing strong momentum with a 47% gain over the past six months.
Duggan's continued investment in Pulse Biosciences underscores his confidence in the company's prospects. Pulse Biosciences is involved in the development of medical devices and technologies, operating within the surgical and medical instruments sector. Based on InvestingPro's Fair Value analysis, the stock appears to be trading above its intrinsic value, despite showing strong momentum with a 47% gain over the past six months.
Duggan's continued investment in Pulse Biosciences underscores his confidence in the company's prospects. Pulse Biosciences is involved in the development of medical devices and technologies, operating within the surgical and medical instruments sector.
In other recent news, Pulse Biosciences has seen significant developments. The company disclosed the departure of its President and CEO, Burke T. Barrett, with interim leadership assumed by Kevin P. Danahy, the Chief Commercial Officer, and Darrin R. Uecker, the Chief Technology Officer. Concurrently, Pulse Biosciences announced encouraging preliminary results from a feasibility study on its Nanosecond Pulsed Field Ablation (nano-PFA) technology, suggesting its potential in reducing benign thyroid nodules.
Furthermore, despite a GAAP net loss of $12.7 million for Q3 2024, the company successfully raised $60 million through a rights offering, ending the quarter with $79 million in cash and cash equivalents. In addition, Pulse Biosciences treated its first Atrial Fibrillation patients in Europe using the nano-PFA Cardiac Surgical System, which has received U.S. FDA breakthrough device designation.
In other developments, major stockholder and Co-Chairman Robert W. Duggan is considering a substantial purchase of the company's common stock. Lastly, the company's nano-PFA technology has shown promise in a study involving 30 patients, with an average reduction in nodule size of over 50% after treatment. These are recent developments from Pulse Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.